Amphastar Pharmaceuticals
AMPH
135 hedge funds and large institutions have $458M invested in Amphastar Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 58 increasing their positions, 39 reducing their positions, and 18 closing their positions.
49% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 39
11% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 18
4% more capital invested
Capital invested by funds: $442M → $458M (+$15.8M)
1% more funds holding
Funds holding: 134 → 135 (+1)
0.3% less ownership
Funds ownership: 48.21% → 47.91% (-0.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$3.81M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$3.37M |
| 3 |
Renaissance Technologies
New York
|
+$2.95M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$2.63M |
| 5 |
Goldman Sachs
New York
|
+$1.83M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$5.51M |
| 2 |
JP Morgan Chase
New York
|
-$2.81M |
| 3 |
Millennium Management
New York
|
-$2.69M |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
-$2.43M |
| 5 |
BlackRock
New York
|
-$1.95M |
AMPH Hedge Fund Activity: Q1 2019 in Review
135 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q1 2019, worth a combined $458M — up 3.6% from $442M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new AMPH positions and 18 closed out — a net gain of 2 holders — while 58 added to existing stakes and 39 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $3.81M. The largest seller was Invesco, cutting an estimated $5.51M.
- 135 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q1 2019, up from 134 in Q4 2018.
- Funds reported $458M of Amphastar Pharmaceuticals stock for Q1 2019, up 3.6% quarter-over-quarter.
- 20 funds opened new Amphastar Pharmaceuticals positions in Q1 2019 and 18 closed out, a net change of +2 holders.
- The largest Amphastar Pharmaceuticals buyer in Q1 2019 was Morgan Stanley, an estimated $3.81M added.
- The largest Amphastar Pharmaceuticals seller in Q1 2019 was Invesco, an estimated $5.51M sold.
Based on aggregated 13F filings for Q1 2019.